Blueprint Protocol (Bryan Johnson)

Blueprint Protocol is Bryan Johnson’s public n-of-1 longevity self-experiment: a measured lifestyle, supplement, diagnostic, clinical, and frontier intervention stack whose transparency is useful, but whose results do not establish a general protocol for other people.

Also known as: Project Blueprint, Don’t Die protocol, Bryan Johnson protocol, Blueprint stack

Context

Bryan Johnson is the most visible public self-experimenter in the longevity field. After selling Braintree and redirecting his resources toward health measurement, he made Project Blueprint into a public protocol: sleep, nutrition, exercise, supplementation, skin and oral care, diagnostics, blood markers, imaging, and selected clinical interventions. In its current public form, the protocol is folded into the broader “Don’t Die” movement and is presented as both a personal health system and a cultural project.

Blueprint’s value is its documentation. Johnson publishes routines, food templates, measurement claims, biomarker snapshots, and protocol updates. The public protocol page also states an important boundary: the program includes on-label, off-label, unlicensed, and research-use-only tests or therapies, reviewed for Johnson’s personal situation by his own clinical and scientific team. That is the right way to read it: as one intensely resourced, repeatedly revised case.

That makes Blueprint different from an ordinary Longevity Clinic, a Fountain-Life-Style Annual Deep Screen, or Concierge Longevity Primary Care. It is not a clinic product sold to many patients under one governance model. It is one person’s public protocol, later commercialized into products, community, apps, events, biomarkers, and media.

Problem

Blueprint is easy to overread because it is unusually complete. The visible stack has meals, timing, supplements, sleep targets, exercise plans, imaging, biomarkers, skin devices, red light, sauna, HBOT experimentation, rapamycin-adjacent clinical discussion in the wider Blueprint orbit, plasma interventions, and gene-therapy attempts discussed in public. A reader can mistake that completeness for transferability.

The evidence problem is structural. Johnson’s data can show what happened to Johnson under Johnson’s conditions, with Johnson’s staff, budget, adherence, baseline history, genetics, preferences, adverse-event tolerance, and willingness to revise. It cannot show that the full protocol extends healthy lifespan in other adults. And when many variables move at once, it cannot tell the reader which component caused which biomarker change.

The practical problem is copying the wrong layer. Some Blueprint components are ordinary health practices with strong evidence: sleep regularity, exercise, alcohol avoidance, high-fiber food patterns, body-composition monitoring, blood-pressure control, and cardiometabolic risk tracking. Other components are clinician-supervised, off-label, investigational, weakly evidenced, cosmetic, commercial, or idiosyncratic. Treating the whole stack as one intervention hides the difference.

Forces

• Transparency increases trust, but it can make an n-of-1 case look stronger than its design supports.
• The most transferable components are often the least theatrical: sleep, training, diet quality, blood pressure, apoB, and social support.
• The expensive components create status pressure even when their evidence is weaker than the cheap components.
• The protocol changes over time, so readers may copy an outdated version or a partial screenshot.
• Commercial products, community identity, and public philosophy can blur the line between documentation and persuasion.
• A personal clinical team can monitor risks that an ordinary reader may not even see.

Solution

Read Blueprint as a component map, not as a prescription. The strong use of the protocol is to separate its parts by evidence tier, cost, availability, regulatory status, and clinical ownership.

The working question is not “Should I follow Blueprint?” It is “Which components have evidence strong enough, risks low enough, and governance clear enough to consider in my situation?” For most readers, the answer starts far below the full stack: sleep timing, resistance training, Zone 2 and interval work, protein adequacy, blood pressure, apoB, glucose context, alcohol avoidance, dental care, and a clinician who can interpret labs.

The advanced components need stricter rules. A reader should not copy a prescription drug, hormone, peptide, plasma procedure, gene-therapy experiment, or device protocol from a public figure’s page. Those components belong inside ordinary medical judgment, with the same diligence applied to any Evaluating a Longevity Clinic decision.

Evidence

Evidence tier: Disputed for the full protocol; component-dependent for the parts. Blueprint as a complete stack has no randomized evidence showing that it extends healthy lifespan, slows clinically meaningful aging, reduces disease incidence, or improves mortality in other adults. The evidence lives at the component level.

The n-of-1 distinction matters. CENT 2015, the CONSORT extension for reporting n-of-1 trials, treats rigorous single-participant evaluation as a real method when it uses planned comparisons, clear outcomes, repeated measurement, adverse-event reporting, and transparent methods. Blueprint has repeated measurement and public documentation, but the public protocol is not a blinded, randomized, multi-crossover n-of-1 trial that can isolate one treatment effect at a time. It is closer to an evolving, multi-component case report plus self-tracking program.

A well-documented case still does work. It can generate hypotheses, show feasibility, reveal adherence systems, and pressure the field to publish better data. Johnson’s public record also makes a cultural point: a person can treat sleep, meals, exercise, biomarkers, and clinical review as one system rather than as disconnected health chores.

The full-stack claim is where the evidence stops. When sleep improves, exercise becomes consistent, diet quality rises, alcohol disappears, weight changes, diagnostics increase, supplements change, procedures occur, and a clinical team monitors the process, the public data cannot cleanly attribute cause. A favorable biological-age score, body-composition result, inflammatory marker, or imaging result may be real. The score still won’t identify which intervention produced it, or whether it predicts fewer clinical events.

The protocol itself acknowledges this uncertainty. The 2026 public page says biological-age claims are preliminary, can be affected by biostatistical errors, and need formal peer-reviewed validation. It also states that the protocol mixes therapies and tests with different licensing status and is based on Johnson’s personal situation. That boundary is stronger than much of the commentary around Blueprint.

Regulatory status varies by component. FDA-regulated gene therapies require investigational applications for clinical studies and biologics-license approval before marketing in the United States. FDA has warned against unapproved regenerative products such as stem cells and exosomes, and against young-donor plasma sold for normal aging or memory claims. None of those warnings rules out every frontier idea. They rule out the inference that access and mechanism count as clinical proof.

How It Plays Out

A 39-year-old founder reads the protocol and wants the “fastest path” to Blueprint. The clean answer is unglamorous: stop alcohol, protect sleep, train consistently, improve food quality, measure blood pressure and basic cardiometabolic markers, and get ordinary preventive care in order. That reader doesn’t need a 100-item stack. They need a stable base.

A 56-year-old with high apoB, poor sleep, and low VO₂max considers buying Blueprint-branded products because Johnson’s biomarker list is impressive. The better first step is clinical triage. ApoB management, blood-pressure control, sleep consistency, resistance training, and aerobic capacity have clearer evidence than most product additions. Supplements may have a role, but they shouldn’t displace the high-yield work.

A 63-year-old sees a public frontier intervention and asks whether to pursue it abroad. The protocol’s existence does not settle the question. The reader still needs product identity, clinician responsibility, jurisdictional status, adverse-event reporting, follow-up care, and domestic records. Otherwise, the decision can drift into Medical Tourism Quality Roulette.

A health coach uses Blueprint with clients as a motivation story. That can work if the coach translates it into principles: measure what matters, build defaults, remove obvious harms, and review changes. It fails when the coach turns Johnson’s personal stack into a list of things a client should buy.

Consequences

Benefits. Blueprint gives the field a public, detailed, repeatedly updated reference case. It shows what extreme measurement discipline looks like when money, staff, time, and adherence are less limiting than they are for most people. It also creates useful pressure on vague wellness claims: if a protocol is serious, it should state what it measures, what changed, what was removed, and where uncertainty remains.

The protocol also helps readers distinguish the boring base from the expensive edge. The base is where most people have the most room to improve. The edge is where evidence, cost, regulation, and risk become harder to inspect.

Liabilities. Blueprint can create a copying reflex. The reader sees the stack, not the governance. They see the biomarker claims without seeing the confounding. The public discipline is visible; the private clinical review behind it is not. The result can be Stack Creep, diagnostic overuse, unnecessary anxiety, or pursuit of frontier interventions before ordinary risks are managed.

The movement layer can also distort medical judgment. “Don’t Die” may help some people care more about their health. It can also turn a personal protocol into identity, and identity makes subtraction harder. If a supplement, test, drug, or procedure stops earning its place, the serious move is to remove it, not defend it because it belongs to the brand.

The practical rule is conservative: study Blueprint for process, not permission. Borrow the discipline of measuring, documenting, reviewing, and revising. Do not borrow clinical or frontier interventions without a qualified clinician, a clear indication, and a separate evidence review for that exact component.

Related Articles

Sources

• Bryan Johnson. “Don’t Die Protocol.” The 2026 public protocol page is the primary source for Johnson’s current self-described routine, biomarkers, measurement plan, disclaimers, and component categories. https://protocol.bryanjohnson.com/
• Bryan Johnson. “Protocol Museum.” The archived Blueprint materials document earlier protocol versions and show how the supplement and routine stack has changed over time. https://protocol-museum.bryanjohnson.com/
• Vohra, Sunita, Larissa Shamseer, Margaret Sampson, et al. “CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.” BMJ 350 (2015): h1738. https://www.bmj.com/content/350/bmj.h1738
• Federal Trade Commission. Health Products Compliance Guidance. December 2022. The guidance anchors the standard that health-related benefit claims need competent and reliable scientific evidence. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
• FDA. “Information About Self-Administration of Gene Therapy.” The page summarizes FDA expectations for investigational gene-therapy studies and marketing approval. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/information-about-self-administration-gene-therapy
• FDA. “Important Patient and Consumer Information About Regenerative Medicine Therapies.” FDA summarizes risks and approval boundaries for marketed regenerative products. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
• FDA. “Important Information about Young Donor Plasma Infusions for Profit.” February 19, 2019. FDA warned that young-donor plasma sold for normal aging and memory claims had no proven clinical benefit and carried plasma-product risks. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-information-about-young-donor-plasma-infusions-profit

Medical and Legal Boundary

This entry is a reference, not medical advice. It describes published evidence, regulatory status, and common clinical practice patterns. It does not diagnose, prescribe, or replace a clinician’s judgment for a specific person.

Blueprint includes lifestyle practices, consumer products, diagnostics, prescription drugs, off-label or investigational components, and frontier interventions whose suitability varies by person and jurisdiction. The existence of a public protocol does not make any component appropriate for a specific reader. Eligibility, dosing, monitoring, contraindications, product identity, jurisdictional status, adverse-event handling, and stopping rules belong to qualified clinicians who can evaluate the individual patient.